Evoke Pharma Reports Second Quarter 2022 Financial Results
10 août 2022 16h05 HE
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases,...
Evoke Pharma to Report Second Quarter Results on August 10, 2022
03 août 2022 08h30 HE
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today...
Evoke Pharma Recognizes Gastroparesis Awareness Month through its Support of The International Foundation for Gastrointestinal Disorders (IFFGD)
01 août 2022 08h30 HE
|
Evoke Pharma, Inc.
Ranked #1 in IFFGD Virtual Walk to spread awareness and support research for gastrointestinal disorders Evoke attending ANMS 2022 meeting August 5-7 in Philadelphia, PA SOLANA BEACH, Calif.,...
Evoke Pharma Announces Approval of GIMOTI® to Florida State Medicaid Program
15 juin 2022 08h30 HE
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., June 15, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
Evoke Pharma Regains Compliance with Nasdaq Listing Requirements and Provides Financial Update
08 juin 2022 08h30 HE
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
Real-World Data Analysis Reveals a Lower Risk of Tardive Dyskinesia (TD) with Metoclopramide than Previously Reported
23 mai 2022 07h00 HE
|
Evoke Pharma, Inc.
Presented as a Poster of Distinction at Digestive Disease Week (DDW) 2022, showed a 98.8 per 100,000 (0.1%) incidence of TD among gastroparesis patients treated with metoclopramide Supports Safety...
Patient Experience Survey Reported Positive Findings for GIMOTI®
18 mai 2022 08h30 HE
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif. and CHICAGO, May 18, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, and...
Evoke Pharma to Present at H.C. Wainwright Global Investment Conference
17 mai 2022 08h30 HE
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
Evoke Pharma Reports First Quarter 2022 Financial Results
10 mai 2022 16h05 HE
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases, today...
Evoke Pharma to Report First Quarter 2022 Financial Results on May 10, 2022
03 mai 2022 08h30 HE
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced...